Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells
- PMID: 20862387
- PMCID: PMC2939389
- DOI: 10.1155/2010/357591
Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells
Abstract
Many details of the molecular and cellular mechanisms involved in Mycobacterium bovis bacillus Calmette-Guérin (BCG) immunotherapy of bladder cancer have been discovered in the past decades. However, information on a potential role for macrophage cytotoxicity as an effector mechanism is limited. Macrophages play pivotal roles in the host innate immunity and serve as a first line of defense in mycobacterial infection. In addition to their function as professional antigen-presenting cells, the tumoricidal activity of macrophages has also been studied with considerable interest. Studies have shown that activated macrophages are potent in killing malignant cells of various tissue origins. This review summarizes the current understanding of the BCG-induced macrophage cytotoxicity toward bladder cancer cells with an intention to inspire investigation on this important but underdeveloped research field.
Similar articles
-
Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.Clin Exp Immunol. 2010 Jun;160(3):359-68. doi: 10.1111/j.1365-2249.2010.04105.x. Epub 2010 Feb 10. Clin Exp Immunol. 2010. PMID: 20148913 Free PMC article.
-
Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.Clin Exp Immunol. 2004 Jul;137(1):24-34. doi: 10.1111/j.1365-2249.2004.02522.x. Clin Exp Immunol. 2004. PMID: 15196240 Free PMC article.
-
Immunotherapy of Bacillus Calmette‑Guérin by targeting macrophages against bladder cancer in a NOD/scid IL2Rg‑/‑ mouse model.Mol Med Rep. 2020 Jul;22(1):362-370. doi: 10.3892/mmr.2020.11090. Epub 2020 Apr 22. Mol Med Rep. 2020. PMID: 32319653 Free PMC article.
-
Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.Int J Urol. 2018 May;25(5):405-413. doi: 10.1111/iju.13538. Epub 2018 Mar 5. Int J Urol. 2018. PMID: 29506322 Review.
-
Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.APMIS. 2020 Feb;128(2):92-103. doi: 10.1111/apm.13011. Epub 2020 Jan 28. APMIS. 2020. PMID: 31755155 Review.
Cited by
-
Immunotherapy for bladder cancer.Res Rep Urol. 2015 May 4;7:65-79. doi: 10.2147/RRU.S63447. eCollection 2015. Res Rep Urol. 2015. PMID: 26000263 Free PMC article. Review.
-
Zinc transporter SLC39A7 relieves zinc deficiency to suppress alternative macrophage activation and impairment of phagocytosis.PLoS One. 2020 Jul 9;15(7):e0235776. doi: 10.1371/journal.pone.0235776. eCollection 2020. PLoS One. 2020. PMID: 32645059 Free PMC article.
-
Innate immune memory is associated with increased disease-free survival in bladder cancer patients treated with bacillus Calmette-Guérin.Can Urol Assoc J. 2021 Aug;15(8):E412-E417. doi: 10.5489/cuaj.7066. Can Urol Assoc J. 2021. PMID: 33410746 Free PMC article.
-
Intravesical Pseudomonas aeruginosa mannose-sensitive Hemagglutinin vaccine triggers a tumor-preventing immune environment in an orthotopic mouse bladder cancer model.Cancer Immunol Immunother. 2022 Jun;71(6):1507-1517. doi: 10.1007/s00262-021-03063-7. Epub 2021 Oct 31. Cancer Immunol Immunother. 2022. PMID: 34718847 Free PMC article.
-
Tumor-associated macrophages and anti-tumor therapies: complex links.Cell Mol Life Sci. 2016 Jul;73(13):2411-24. doi: 10.1007/s00018-016-2166-5. Epub 2016 Mar 8. Cell Mol Life Sci. 2016. PMID: 26956893 Free PMC article. Review.
References
-
- Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors. Journal of Urology. 1976;116(2):180–183. - PubMed
-
- Alexandroff AB, Jackson AM, O’Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353(9165):1689–1694. - PubMed
-
- Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial madder cancer: a review. Urological Research. 1998;26(3):155–159. - PubMed
-
- Ratliff TL, Ritchey JK, Yuan JJJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. Journal of Urology. 1993;150(3):1018–1023. - PubMed
-
- Wang R, Rogers AM, Ratliff TL, Russell JH. CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. Journal of Immunology. 1996;157(7):2961–2968. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous